In addition to the above metabolic outcomes, GLP-1R agonists are able to induce sustained weight loss through appetite suppression and delayed gastric emptying, ultimately leading to the commercialization of the once daily liraglutide for chronic weight management in patients with obesity [4]. This evidence concerns the gene GLP1R and obesity disorder.